adenine has been researched along with Psoriasis in 14 studies
Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Psoriasis is a chronic, inflammatory disease affecting 2-3% of the worldwide population, and it may worsen with HIV or be detected as HIV cutaneous manifestation." | 6.48 | Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir). ( Cannizzaro, MV; Chimenti, S; Chiricozzi, A; Giunta, A; Nisticò, SP; Saraceno, R, 2012) |
| "Psoriasis is an unchecked chronic inflammation characterized by thick, erythematous, and scaly plaques on the skin." | 5.56 | Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells. ( Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Alanazi, WA; Alasmari, AF; Alasmari, F; Attia, SM; Bakheet, SA; El-Sherbeeny, AM; Ibrahim, KE; Nadeem, A, 2020) |
| "Psoriasis is clinically characterized by well-demarcated silvery plaques which may appear on the extremities, scalp, and sacral area." | 5.56 | Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells. ( Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Alotaibi, MR; Alqahtani, F; Alzahrani, KS; Attia, SM; Bakheet, SA; El-Sherbeeny, AM; Ibrahim, KE; Mahmood, HM; Nadeem, A, 2020) |
| "Psoriasis is a chronic, inflammatory disease affecting 2-3% of the worldwide population, and it may worsen with HIV or be detected as HIV cutaneous manifestation." | 2.48 | Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir). ( Cannizzaro, MV; Chimenti, S; Chiricozzi, A; Giunta, A; Nisticò, SP; Saraceno, R, 2012) |
| "Because psoriasis is not cured by PUVA, patients receive many treatments over their lifetime and develop a significant risk for the development of skin cancers (primarily squamous cell carcinomas)." | 2.40 | Psoriasis, PUVA, and skin cancer--molecular epidemiology: the curious question of T-->A transversions. ( Gasparro, FP; Peritz, AE, 1999) |
| "Psoriasis is the most prevalent inflammatory skin disorders, affecting 1-3% of the worldwide population." | 1.62 | DZ2002 alleviates psoriasis-like skin lesions via differentially regulating methylation of GATA3 and LCN2 promoters. ( Cao, S; Chen, L; He, S; Huang, Y; Lin, Z; Liu, Y; Tang, W; Yang, X; Zhu, F; Zuo, J, 2021) |
| "Psoriasis is an unchecked chronic inflammation characterized by thick, erythematous, and scaly plaques on the skin." | 1.56 | Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells. ( Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Alanazi, WA; Alasmari, AF; Alasmari, F; Attia, SM; Bakheet, SA; El-Sherbeeny, AM; Ibrahim, KE; Nadeem, A, 2020) |
| "Psoriasis is clinically characterized by well-demarcated silvery plaques which may appear on the extremities, scalp, and sacral area." | 1.56 | Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells. ( Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Alotaibi, MR; Alqahtani, F; Alzahrani, KS; Attia, SM; Bakheet, SA; El-Sherbeeny, AM; Ibrahim, KE; Mahmood, HM; Nadeem, A, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Kishimoto, M | 1 |
| Komine, M | 1 |
| Kamiya, K | 1 |
| Sugai, J | 1 |
| Kuwahara, A | 1 |
| Morimoto, N | 1 |
| Ohtsuki, M | 1 |
| Nadeem, A | 2 |
| Ahmad, SF | 2 |
| Al-Harbi, NO | 2 |
| El-Sherbeeny, AM | 2 |
| Alasmari, AF | 1 |
| Alanazi, WA | 1 |
| Alasmari, F | 1 |
| Ibrahim, KE | 2 |
| Al-Harbi, MM | 2 |
| Bakheet, SA | 2 |
| Attia, SM | 2 |
| Alzahrani, KS | 1 |
| Mahmood, HM | 1 |
| Alqahtani, F | 1 |
| Alotaibi, MR | 1 |
| Chen, L | 1 |
| Lin, Z | 1 |
| Liu, Y | 1 |
| Cao, S | 1 |
| Huang, Y | 1 |
| Yang, X | 1 |
| Zhu, F | 1 |
| Tang, W | 2 |
| He, S | 1 |
| Zuo, J | 1 |
| Lin, ZM | 1 |
| Ma, M | 1 |
| Li, H | 1 |
| Qi, Q | 1 |
| Liu, YT | 1 |
| Yan, YX | 1 |
| Shen, YF | 1 |
| Yang, XQ | 1 |
| Zhu, FH | 1 |
| He, SJ | 1 |
| Zuo, JP | 1 |
| Martin, L | 1 |
| Chiricozzi, A | 1 |
| Saraceno, R | 1 |
| Cannizzaro, MV | 1 |
| Nisticò, SP | 1 |
| Chimenti, S | 1 |
| Giunta, A | 1 |
| Núñez-Rodríguez, MH | 1 |
| Santamaría-Martínez, A | 1 |
| Mata-Román, L | 1 |
| Caro-Patón, A | 1 |
| Partsch, G | 1 |
| Mayer, F | 1 |
| Eberl, R | 1 |
| Luger, A | 1 |
| Dybdahl, M | 1 |
| Vogel, U | 1 |
| Frentz, G | 1 |
| Wallin, H | 1 |
| Nexø, BA | 1 |
| Peritz, AE | 1 |
| Gasparro, FP | 1 |
| Mui, MM | 1 |
| Hsia, SL | 3 |
| Halprin, KM | 3 |
| Wright, R | 1 |
| Mandy, SH | 2 |
| Wright, RK | 1 |
3 reviews available for adenine and Psoriasis
| Article | Year |
|---|---|
[What's new in dermatological treatments?].
Topics: Adenine; Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic | 2010 |
Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir).
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; | 2012 |
Psoriasis, PUVA, and skin cancer--molecular epidemiology: the curious question of T-->A transversions.
Topics: Adenine; Carcinoma, Squamous Cell; Humans; Psoriasis; PUVA Therapy; Skin Neoplasms; Thymidine; Tumor | 1999 |
11 other studies available for adenine and Psoriasis
| Article | Year |
|---|---|
Case of psoriasis with hepatitis B virus infection during tumor necrosis factor inhibitor treatment successfully treated with ixekizumab and tenofovir alafenamide fumarate.
Topics: Adenine; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Fumarates; Hepatitis B; Hepat | 2022 |
Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Dendritic Cells; Disease Models, Animal; Huma | 2020 |
Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells.
Topics: Adenine; Animals; BALB 3T3 Cells; Dendritic Cells; Down-Regulation; Imiquimod; Inflammation Mediator | 2020 |
DZ2002 alleviates psoriasis-like skin lesions via differentially regulating methylation of GATA3 and LCN2 promoters.
Topics: Adenine; Animals; Anti-Inflammatory Agents; Butyrates; Cell Differentiation; Cell Proliferation; Che | 2021 |
Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-α/IFN-γ-induced inflammatory response in keratinocytes and T cell-derived IL-17.
Topics: Adenine; Adenosylhomocysteinase; Administration, Topical; Animals; Anti-Inflammatory Agents; Butyrat | 2018 |
[Reactivation of hepatitis B treated with adefovir after infliximab administration].
Topics: Adenine; Antibodies, Monoclonal; Antiviral Agents; Hepatitis B; Humans; Immunosuppressive Agents; In | 2006 |
Salvage pathway in erythrocytes of patients with psoriasis.
Topics: Adenine; Adenine Nucleotides; Carbon Radioisotopes; Erythrocytes; Guanine; Humans; Hypoxanthines; Ps | 1980 |
Polymorphisms in the DNA repair gene XPD: correlations with risk and age at onset of basal cell carcinoma.
Topics: Adenine; Adult; Age Factors; Age of Onset; Alleles; Carcinoma, Basal Cell; Confidence Intervals; Cyt | 1999 |
Further studies on adenyl cyclase in psoriasis.
Topics: Adenine; Adenosine Triphosphate; Adenylyl Cyclases; Cyclic AMP; Epinephrine; Humans; Kinetics; Propr | 1975 |
Adenyl cyclase in normal and psoriatic skin.
Topics: Adenine; Adenylyl Cyclases; Autoradiography; Carbon Isotopes; Cyclic AMP; Epinephrine; Fluorides; Gl | 1972 |
Defects and deficiency of adenyl cyclase in psoriatic skin.
Topics: Adenine; Adenylyl Cyclases; Adult; Carbon Isotopes; Cyclic AMP; Epinephrine; Fluorides; Glucose; Hum | 1973 |